Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Esterified butyrate, specifically delivered as butyrylated high-amylose maize starch (HAMSB), is a dietary intervention developed by the CSIRO Preventative Health National Research Flagship for the chemoprevention of colorectal cancer, particularly in patients with familial adenomatous polyposis (FAP). In this formulation, butyrate, a short-chain fatty acid (SCFA), is chemically esterified to a high-amylose maize starch backbone. This delivery system allows the butyrate to bypass the upper gastrointestinal tract and be released in the colon through bacterial fermentation of the starch. Once released, butyrate serves as a primary energy source for colonocytes and acts as a histone deacetylase (HDAC) inhibitor, promoting cell cycle arrest and apoptosis in neoplastic cells while supporting healthy colonic epithelial function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on esterified butyrate.